CompletedPhase 4NCT02027311
Etomidate vs. Midazolam for Sedation During ERCP
Studying Cholangiocarcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cheju Halla General Hospital
- Principal Investigator
- BYUNG HYO CHA, Dr.Cheju Halla General Hospital, Doreongno 65, Jeju-si Jeju Special Self-Governing Province, Korea 690-766
- Intervention
- Etomidate(drug)
- Enrollment
- 63 target
- Eligibility
- 20-90 years · All sexes
- Timeline
- 2013 – 2013
Study locations (1)
- 1Digestive Disease Center and Department of Internal Medicine, Cheju Halla General Hospital, Jeju City, Jeju Special Self-Governing Province, South Korea
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02027311 on ClinicalTrials.govOther trials for Cholangiocarcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07478523FAPI-PET Value for the Initial Screening of Pancreatic and Biliary CancersUniversity Hospital, Bordeaux
- RECRUITINGNANCT07476651Scout Dose of Resin MicrospheresSeoul National University Hospital
- RECRUITINGPHASE2NCT06728410A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or RearrangementMehmet Akce
- RECRUITINGPHASE2NCT07223307REGULUS: MRI-guided Adaptive SABR for Liver CancersStanford University
- RECRUITINGPHASE2NCT07201519Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion ChemotherapyMichael J Cavnar, MD
- RECRUITINGPHASE2NCT07260175Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 CholangiocarcinomaInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- RECRUITINGNANCT06735560Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NENNantes University Hospital
- RECRUITINGNCT07206355In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary CancersUniversity of Nottingham